• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cambridge Heart loses coverage decision at WellPoint

Cambridge Heart loses coverage decision at WellPoint

April 24, 2009 By MassDevice staff

One of the largest private insurers in the world will no longer cover a test that Cambridge Heart Inc. says can predict the risk of a sudden heart attack.

Indianapolis-based WellPoint changed its stance on the Tewksbury-based diagnostics firm’s Microvolt T-Wave Alternans test, moving it from a covered to a non-covered service. WellPoint cited results from recent clinical trials as one reason for its decision.

The company is an independent licensee of the Blue Cross/Blue Shield health insurance system across the country. More than 35 million people get their health insurance through a WellPoint affiliate, according to the company’s website.

The insurance giant’s previous coverage included use of the test for patients who were candidates for implantable cardioverter defibrillators.

Cambridge Heart, which likens the MTWA test to a simple treadmill stress test, has been dogged by reimbursement woes. The company has had difficulty getting the MTWA test covered by some of the largest private health insurers in the world, including United Health and several Blue Cross/Blue Shield affiliates, according to its most recent quarterly report.

Company officials expressed disappointment at the news of another reimbursement setback, estimating that WellPoint’s decision would affect about 16 percent of patients covered by private insurers.

However, “given the narrow scope of the original policy, this revision is expected to impact less than 2 percent of the estimated 6,000,000 high-risk cardiac patients currently covered for MTWA testing by either Medicare or other commercial health plans in the United States,” they said.

The disappointing news comes on the heels of a bad year for the company. Cambridge Heart reported that sales dropped a whopping 58 percent in 2008, to $4.2 million, which the company blamed on troubles with a marketing deal with medical device giant St. Jude Medical and an overhaul of the company’s sales pipelines. The soft revenues pushed net losses to $10.3 million for the year, compared to $9.9 million during 2007.

Filed Under: Business/Financial News, Diagnostics

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy